Literature DB >> 12845558

Testosterone undecanoate: a useful tool for testosterone administration in rats.

F Callies1, U Kollenkirchen, C von zur Mühlen, M Tomaszewski, S Beer, B Allolio.   

Abstract

A major obstacle of testosterone (T) treatment in experimental animals is the difficulty of maintaining long-term physiologic/anabolic steady serum levels after exogenous T administration. In two complementary studies we investigated the pharmacokinetic properties of different T formulations in male rats. Study I. Mature male Wistar rats (> 380 g, n = 4 - 7/group) were divided into four treatment groups: (1) sham-operated non orchiectomised (non-ORX) and placebo; (2) orchiectomised (ORX) and subcutaneous testosterone pellets (TP) (15, 25, 75 mg/60 days release or placebo pellets); (3) ORX and a single injection of testosterone undecanoate (TUD) (31, 62.5 or 125 mg/kg body weight subcutaneously (s.c.) or vehicle; (4) ORX and testosterone propionate (Tprop) (10, 20, 40 mg/month) or vehicle as a single injection s.c. Serum T was measured at baseline and in weekly intervals for 4 weeks. Study II. Mature male Wistar rats (180 - 200 g) were randomly assigned to one of 5 experimental groups (n = 5 - 6/group): (1) normal untreated rats (controls); (2) ORX untreated rats, and non-ORX rats receiving one of three treatment options; (3) 250 mg/kg body weight TUD i.m. (TUD 250); (4) 500 mg/kg body weight TUD i.m. (TUD 500); (5) 100-mg testosterone pellet/90 days release s.c. (TP 100). Serum T was measured at baseline and in intervals for 6 weeks after T administration. In both studies, the kinetic profile of TUD showed favourable continuous steady state levels over several weeks. In contrast, testosterone release by subcutaneous pellets resulted in a shorter than expected duration of elevated serum T levels with high inter-individual variability. Tprop administration led to only a short-lasting serum T increase with low serum T levels already 14 days after injection. In conclusion, a single injection of TUD (100 mg/kg body weight s.c.) is effective in inducing physiological testosterone levels in ORX rats for a minimum of four weeks. High dose TUD (500 mg/kg body weight i.m.) given as a single injection results in supraphysiological anabolic testosterone concentrations for up to six weeks in non-ORX rats. TUD was superior to other T release preparations and represents a convenient and effective tool for T administration in experimental animals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845558     DOI: 10.1055/s-2003-40464

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  8 in total

1.  Effect of orchiectomy and testosterone replacement on lower urinary tract function in anesthetized rats.

Authors:  Chen-Li Cheng; William C de Groat
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-17

2.  Sex differences and hormonal modulation of ethanol-enhanced risk taking in rats.

Authors:  Kathryn G Wallin-Miller; Jordyn Chesley; Juliana Castrillon; Ruth I Wood
Journal:  Drug Alcohol Depend       Date:  2017-03-07       Impact factor: 4.492

3.  Effect of testosterone therapy on the urinary bladder in experimental hypogonadism of rats.

Authors:  Ahmed A M Abdel-Hamid; Eyad M T Ali
Journal:  J Mol Histol       Date:  2015-03-26       Impact factor: 2.611

4.  The prostate after castration and hormone replacement in a rat model: structural and ultrastructural analysis.

Authors:  Bruno Felix-Patrício; Alexandre F Miranda; Jorge L Medeiros; Carla B M Gallo; Bianca M Gregório; Diogo B Souza; Waldemar S Costa; Francisco J B Sampaio
Journal:  Int Braz J Urol       Date:  2017 Sep-Oct       Impact factor: 1.541

5.  The effects of supraphysiological levels of testosterone on neural networks upstream of gonadotropin-releasing hormone neurons.

Authors:  Mohammad Saied Salehi; Homayoun Khazali; Fariba Mahmoudi; Mahyar Janahmadi
Journal:  Iran J Basic Med Sci       Date:  2019-09       Impact factor: 2.699

6.  Comparative application of testosterone undecanoate and/or testosterone propionate in induction of benign prostatic hyperplasia in Wistar rats.

Authors:  Jinho An; Hyunseok Kong
Journal:  PLoS One       Date:  2022-05-18       Impact factor: 3.240

Review 7.  Testosterone depot injection in male hypogonadism: a critical appraisal.

Authors:  Aksam A Yassin; Mohamed Haffejee
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

8.  Testosterone replacement maintains smooth muscle content in the corpus cavernosum of orchiectomized rats.

Authors:  Graziele Halmenschlager; Ernani Luis Rhoden; Gabriela Almeida Motta; Lucas Sagrillo Fagundes; Jorge Luiz Medeiros; Rosalva Meurer; Cláudia Ramos Rhoden
Journal:  Asian J Urol       Date:  2017-02-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.